Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 9/20 | 0.66 |
| ▸ | GSK3B | P49841 | 4/20 | 0.66 |
| ▸ | MERTK | Q12866 | 8/20 | 0.59 |
| ▸ | AXL | P30530 | 4/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493948 | 0.93 | AKT2 (0.63) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3490881 | 0.91 | AKT2 (0.63) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL2782083 | 0.90 | AKT2 (0.59) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3492164 | 0.89 | AXL (0.62) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3493066 | 0.89 | AKT2 (0.60) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3492789 | 0.89 | AKT2 (0.60) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3491325 | 0.88 | AKT2 (0.59) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3491619 | 0.88 | AKT2 (0.59) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3491375 | 0.87 | AKT2 (0.60) | AKT2GSK3BMERTKAXLTYRO3 | |
| SCHEMBL3492871 | 0.87 | AKT2 (0.67) | AKT2GSK3BJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | AKT2 71/4885GSK3B 31/4885MERTK 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.